Wilson Baber, MD
Ophthalmology · Shreveport, LANPI 1386649788
Payments from drug & device makers
Across 49 payments — averaging $82.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dutch Ophthalmic, USA$2K
- Genentech USA, Inc.$547
- Apellis Pharmaceuticals, Inc.$390
- Mallinckrodt Hospital Products Inc.$173
- Carl Zeiss Meditec USA, Inc.$169
- Sight Sciences, Inc.$134
- plus $333 from 10 others
What the payments were for
- Consulting fees$2,25055%
- Food & beverage$1,71142%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dutch Ophthalmic, USA | 4 | $2,315 |
| Genentech USA, Inc. | 11 | $547 |
| Apellis Pharmaceuticals, Inc. | 13 | $390 |
| Mallinckrodt Hospital Products Inc. | 4 | $173 |
| Carl Zeiss Meditec USA, Inc. | 1 | $169 |
| Sight Sciences, Inc. | 1 | $134 |
| Biogen | 3 | $62 |
| Kala Pharmaceuticals, Inc. | 3 | $61 |
| Iridex Corporation | 1 | $44 |
| Eyepoint US, Inc. | 2 | $43 |
| Harrow Eye, LLC | 1 | $28 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Novartis | 1 | $19 |
| Omeros Corporation | 1 | $17 |
| Ivantis, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVA, combined machine$2,250
- Lucentis$233
- VABYSMO$148
- OMNI(R) SURGICAL SYSTEM (US)$134
- Syfovre$125
How this compares
$4,061 in reported general payments places this provider in the 70th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 350 | $16,263 |
| Atropine Sulfate | 121 | $4,545 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $3,801 |
| Ketorolac Tromethamine | 157 | $3,065 |
| Brimonidine Tartrate | 34 | $1,836 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 107 | $874 |
| Tobramycin | 158 | $797 |
| Timolol Maleate | 59 | $747 |
| Latanoprost | 30 | $178 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $155 |
| Prednisone | 62 | $137 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Shreveport
- Wyche ColemanShreveport$130K
- Christopher ShelbyShreveport$39K
- Claude BundrickShreveport$36K
- Bryan VekoviusShreveport$29K
- Chanping LiangShreveport$15K
- Bryan LuskShreveport$10K
- Arthur KavanaughShreveport$7K
- Ann GuyShreveport$6K
- Jeffrey LuskShreveport$5K
- Blake WilliamsonBaton Rouge$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.